Is Tirzepatide the New Game Changer in Type 2 Diabetes?

Is Tirzepatide the New Game Changer in Type 2 Diabetes?

<b>Background:</b> Tirzepatide (TZP) is a once-weekly glucagon-like peptide 1 (GLP-1) and glucose-dependent-insulinotropic-polypeptide (GIP) receptor co-agonist approved for T2D. TZP provides promising evidence in improving glucose control and weight loss in T2D and obesity across precli...

Full description

Bibliographic Details
Main Authors:	Giuseppe Lisco, Olga Eugenia Disoteo, Vincenzo De Geronimo, Anna De Tullio, Vito Angelo Giagulli, Edoardo Guastamacchia, Giovanni De Pergola, Emilio Jirillo, Vincenzo Triggiani
Format:	Article
Language:	English
Published:	MDPI AG 2024-02-01
Series:	Endocrines
Subjects:	tirzepatide type 2 diabetes glycemic control weight loss cardiovascular outcomes renal outcomes
Online Access:	https://www.mdpi.com/2673-396X/5/1/5

Similar Items

Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis
by: Giuseppe Lisco, et al.
Published: (2022-09-01)

The effects of subcutaneous Tirzepatide on obesity and overweight: a systematic review and meta‐regression analysis of randomized controlled trials
by: Pejman Rohani, et al.
Published: (2023-08-01)

Tirzepatide-induced ketoacidosis in non-diabetic patients
by: Pathan Mohamad Rafe Iqbal, et al.
Published: (2024-03-01)

Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age
by: Giuseppe Lisco, et al.
Published: (2023-12-01)

The Upcoming Weekly Tides (Semaglutide vs. Tirzepatide) against Obesity: STEP or SURPASS?
by: Han Na Jung, et al.
Published: (2022-03-01)

Generalizability of the SURPASS‐2 Trial and Effect of Tirzepatide on US Diabetes and Obesity Control
by: Nicholas Chiu, et al.
Published: (2022-08-01)

Dopamine in the Regulation of Glucose Homeostasis, Pathogenesis of Type 2 Diabetes, and Chronic Conditions of Impaired Dopamine Activity/Metabolism: Implication for Pathophysiological and Therapeutic Purposes
by: Giuseppe Lisco, et al.
Published: (2023-11-01)

Age-Related Male Hypogonadism and Cognitive Impairment in the Elderly: Focus on the Effects of Testosterone Replacement Therapy on Cognition
by: Giuseppe Lisco, et al.
Published: (2020-10-01)

Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
by: Vivek P. Chavda, et al.
Published: (2022-07-01)

Tirzepatide as a novel effective and safe strategy for treating obesity: a systematic review and meta-analysis of randomized controlled trials
by: Wenting Cai, et al.
Published: (2024-01-01)

Novel Dual Incretin Receptor Agonists in the Spectrum of Metabolic Diseases with a Focus on Tirzepatide: Real Game-Changers or Great Expectations? A Narrative Review
by: Alexandros Leonidas Liarakos, et al.
Published: (2023-07-01)

Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
by: Ricardo J. Samms, et al.
Published: (2022-10-01)

Designing a Dual GLP-1R/GIPR Agonist from Tirzepatide: Comparing Residues Between Tirzepatide, GLP-1, and GIP
by: Wang L
Published: (2022-05-01)

The role of male hypogonadism, aging, and chronic diseases in characterizing adult and elderly men with erectile dysfunction: a cross-sectional study
by: Giuseppe Lisco, et al.
Published: (2023-04-01)

Signal Transduction of Mineralocorticoid and Angiotensin II Receptors in the Central Control of Sodium Appetite: A Narrative Review
by: Michele Iovino, et al.
Published: (2021-10-01)

Reduction of prevalence of patients meeting the criteria for metabolic syndrome with tirzepatide: a post hoc analysis from the SURPASS Clinical Trial Program
by: Stephen J. Nicholls, et al.
Published: (2024-02-01)

Tirzepatide for type 2 diabetes
by: Sarah L Anderson, et al.
Published: (2023-08-01)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
by: Rachel Sinha, et al.
Published: (2023-03-01)

The Potential Utility of Tirzepatide for the Management of Polycystic Ovary Syndrome
by: Alekya Devi Anala, et al.
Published: (2023-07-01)

Efficacy and safety of tirzepatide in patients with type 2 diabetes mellitus: A bayesian network meta-analysis
by: Ruifang Guan, et al.
Published: (2022-10-01)

The Effect of Tirzepatide on Weight, Lipid Metabolism and Blood Pressure in Overweight/Obese Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
by: Lv X, et al.
Published: (2024-02-01)

Iodine Deficiency and Iodine Prophylaxis: An Overview and Update
by: Giuseppe Lisco, et al.
Published: (2023-02-01)

Interference on Iodine Uptake and Human Thyroid Function by Perchlorate-Contaminated Water and Food
by: Giuseppe Lisco, et al.
Published: (2020-06-01)

Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis
by: Deep Dutta, et al.
Published: (2021-01-01)

Evidence that tirzepatide protects against diabetes-related cardiac damages
by: Fatemeh Taktaz, et al.
Published: (2024-03-01)

Optimal dose of tirzepatide for type 2 diabetes mellitus: A meta-analysis and trial sequential analysis
by: Yunfeng Yu, et al.
Published: (2022-08-01)

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Phase II/III Trials
by: Akshaya Srikanth Bhagavathula, et al.
Published: (2021-09-01)

Glucagon-like peptide 1 receptor agonists and thyroid cancer: is it the time to be concerned?
by: Giuseppe Lisco, et al.
Published: (2023-10-01)

Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis
by: Yanan Ding, et al.
Published: (2024-01-01)

Tirzepatide ameliorates spatial learning and memory impairment through modulation of aberrant insulin resistance and inflammation response in diabetic rats
by: Xiying Guo, et al.
Published: (2023-08-01)

Efficacy and safety of tirzepatide in patients with type 2 diabetes: A systematic review and meta-analysis
by: Yan Tang, et al.
Published: (2022-10-01)

Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling
by: Ruifang Guan, et al.
Published: (2023-11-01)

Next Generation Antiobesity Medications: Setmelanotide, Semaglutide, Tirzepatide and Bimagrumab: What do They Mean for Clinical Practice?
by: Donna H. Ryan
Published: (2021-09-01)

The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects
by: Jensen TL, et al.
Published: (2024-02-01)

Incretin Therapies for Patients with Type 2 Diabetes and Chronic Kidney Disease
by: Radica Z. Alicic, et al.
Published: (2023-12-01)

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist
by: Rouchan Ali, et al.
Published: (2022-09-01)

COVID-19 and the Endocrine System: A Comprehensive Review on the Theme
by: Giuseppe Lisco, et al.
Published: (2021-06-01)

Clinical Research Progress of Tirzepatide: a New Hypoglycemic Agent
by: ZHANG Lina, WANG Yan, ZHANG Kanghuai, LI Youjia
Published: (2023-05-01)

Tirzepatide - a novel dual GLP-1 and GIP receptor agonist used in pharmacotherapy of obesity: A literature review
by: Bartłomiej Stachyra, et al.
Published: (2023-04-01)

Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
by: Ildiko Lingvay, et al.
Published: (2023-03-01)